Trospium Chloride Capsule, Extended Release
Product Images NDC 70010-027

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Trospium Chloride (NDC 70010-027). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Granules Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Trospium-er-jpg (Trospium Er Jpg)

Label for TROSPIUM CHLORIDE Extended-Release Capsules, 60 mg, oral dosage form by Granules Pharmaceuticals Inc. The label indicates a 30-capsule package with once-daily dosing. Storage instructions specify keeping the capsules in a tight, light-resistant container between 20° to 25°C with allowed excursions. The product is prescription only.*

FDA Label Image

Trosoiumstructure-jpg (Trospium Stucture Jpg)

Chemical structure diagram of the active ingredient Trospium Chloride, displaying its molecular arrangement including a quaternary ammonium ion and benzene rings.*

FDA Label Image

Trospiumgraph1-jpg (Trospiumgraph1 Jpg)

A line graph showing plasma concentration (mg/mL) over time in hours post-dose for Trospium chloride extended-release capsules 60 mg. The graph indicates plasma levels rising to a peak around 4-6 hours then gradually declining up to 24 hours, with error bars at each time point.*

FDA Label Image

Trospiumgraph2-jpg (Trospiumgraph2 Jpg)

Line graph comparing average change over time in a measured variable between placebo and Trospium chloride extended-release capsules (60 mg) across 0, 1, 4, and 12 weeks of treatment. The graph includes error bars and statistical significance values indicating differences between groups at various time points.*

FDA Label Image

Trospiumgraph3-jpg (Trospiumgraph3 Jpg)

A line graph showing the average percentage change over 12 weeks of treatment comparing placebo to Trosopium Chloride extended-release capsules. The graph includes error bars and p-values indicating statistical significance at weeks 1, 4, and 12.*

FDA Label Image

Trospiumgraph4-jpg (Trospiumgraph4 Jpg)

Line graph showing average change with standard error over 12 weeks of treatment comparing placebo and TROSPIUM CHLORIDE extended-release capsules. The x-axis represents weeks of treatment (0, 1, 4, 12) and the y-axis shows average change. Data points for placebo and TROSPIUM CHLORIDE groups are plotted with associated p-values at weeks 1, 4, and 12.*

FDA Label Image

Trospiumgraph5-jpg (Trospiumgraph5 Jpg)

A line graph comparing the average change over 12 weeks of treatment between placebo and trosium chloride extended-release capsules. The x-axis represents the weeks of treatment (0, 1, 4, 12), and the y-axis shows the average change with standard error. Two lines depict placebo and trosium chloride groups, with significant differences (p<0.001) noted at weeks 1, 4, and 12.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.